Panelists discuss how AML treatment has entered an exciting era of personalized medicine with increasing oral options and targeted therapies, while identifying immunotherapy as a major unmet need and expressing optimism about patients achieving long-term survival on current regimens.
The group describes the clinical gaps that prompted development of bispecifics and summarizes the currently available agents for relapsed/refractory disease.
Panelists discuss how integrating clinical efficacy with cost-effectiveness ensures sustainable adoption of MASH therapies.
Panelists discuss how next-generation metabolic and hepatic agents are broadening treatment options and reshaping the MASH care landscape.
Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.
Panelists discuss how nonstatin agents are chosen and when combination therapy should be introduced for high-risk patients.
Panelists discuss how global LDL thresholds below 55 mg/dL influence care and challenge U.S. practice to evolve.
Panelists discuss how overcoming logistical and perceptual barriers will drive wider adoption of SC therapies in NSCLC.
Panelists discuss how SC formulations streamline pharmacy workflows and optimize oncology practice efficiency.
While limited data suggest loncastuximab tesirine plus rituximab may be active in the third line, larger cohorts and longer-term data are needed to definitively determine its effectiveness.
Zachary Contreras from Sharp Health Plan explains how managed care organizations can support early adoption of DM-BUP to prevent high-cost care episodes, emphasizing the need for predictive analytics, streamlined access, and real-world comparative data to guide treatment sequencing decisions.
Zachary Contreras from Sharp Health Plan discusses findings from the AMCP Nexus study showing that dextromethorphan-bupropion (DM-BUP) was associated with lower total health care costs compared with other therapies, outlining strategies managed care organizations can use to promote cost-effective treatment adoption.
Combination tafasitamab, lenalidomide, and rituximab is a recommended second-line regimen based on the phase 3 InMIND trial.
Panelists discuss how future AML treatment will likely involve sophisticated decisions about triplet combinations, optimal sequencing of targeted agents, and balancing efficacy with toxicity through either upfront intensive approaches or thoughtful sequential doublet therapies.
Patients with desmoid tumors face significant clinical and economic burdens, impacting their quality of life and leading to ongoing treatment challenges.
Panelists discuss how combining effective antipsychotic medications for positive symptoms with digital therapeutics for negative symptoms could synergistically improve overall outcomes and help young patients achieve their life goals.
Explore the critical role of biomarkers in diagnosing desmoid tumors and the importance of early detection for patient quality of life.
Panelists discuss how payer access challenges can determine whether patients receive therapy at all, with strategies including hospitalization for first cycles, advance prescription preparation, and recognition that oral regimens significantly impact quality of life for patients requiring lifelong treatment.
Panelists discuss how prescription digital therapeutics can expand access to specialized mental health interventions in underserved rural communities where traditional therapy resources are scarce or unavailable.
Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.
Panelists discuss how GLP-1 therapies show dual metabolic and hepatic benefits, redefining MASH management.
Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.
Panelists discuss how recognizing high-risk patients and linking liver care with metabolic management can reduce both disease and economic impact.
Panelists discuss how reinstating LDL-C targets in quality programs could improve outcomes and accountability.
Panelists discuss how substituting LDL outcomes with statin-use metrics weakened cholesterol management quality.
Panelists discuss how SC formulations enhance adherence through simpler, patient-friendly treatment delivery.
Panelists discuss how shared decision-making empowers patients when choosing between IV and SC administration routes.
Panelists discuss how support networks and coordinated care are essential for delivering third-line metastatic colorectal cancer therapies effectively in the community.
Panelists discuss how addressing barriers and sharing real-world data can increase community confidence in prescribing third-line metastatic colorectal therapies.
Panelists discuss how digital therapeutics could address the enormous unmet need for treating negative symptoms in the 60% of patients with schizophrenia who experience them, potentially reducing health care costs and improving quality of life.
259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
